Article Text

Download PDFPDF

Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.
  1. W Mahattanakul,
  2. T O Crawford,
  3. J W Griffin,
  4. J M Goldstein,
  5. D R Cornblath
  1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.


    Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated polyneuropathy for which there are effective therapies. However, not all patients improve with these treatments. Eight patients with CIDP, two with IgG monoclonal gammopathies, were treated with cyclosporin-A (3 to 5 mg/kg/day). In three, this treatment was successful. It was unsuccessful in four patients who were resistant to other treatments and in one who had initially received cyclosporin-A. There were no serious side effects. In selected patients with CIDP, cyclosporin-A is a potentially useful treatment.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.